Patient Voices Swayed FDA's Imlygic Review Team
Executive Summary
Testimony from patients about the cosmetic and psychological advantages of seeing melanoma lesions shrink was a key element in agency's decision to offer full approval to Amgen's talimogene laherparepvec despite serious concerns about the clinical meaning of the pivotal trial's durable response rate endpoint.
You may also be interested in...
Case Studies In FDA's Regulatory Interpretation Of Clinical Trials
For more than 15 years, the Pink Sheet's Drug Review Profile series has looked closely at FDA approval documents, providing a long view of the pitfalls and pitches presented in the NEJM series on interpreting clinical trial results.
Choice Of Regulatory Pathway Is Key Inflection Point In Drug Reviews
A year of Drug Review Profiles in the Pink Sheet shows how important the choice of regulatory pathway has become to drug development and approval.
Oncology PROs: Limited Use Due To Small Trials, Fast Drug Development
Patient-reported outcomes in oncology clinical trials remain an infrequently used tool, despite acknowledgement by sponsors that the patient experience is important to measure – and encouragement from FDA officials to do so. The lack of PROs in oncology may be a byproduct of the fast pace of cancer drugs are developed in the U.S.: small trials and accelerated pathways.